Drug Profile
Peginterferon alpha 2b biosimilar - Zydus Cadila
Alternative Names: Peg IFN α-2b; PegiHep; Pegylated interferon alpha-2b; VirafinLatest Information Update: 18 Jul 2022
Price :
$50
*
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Antiretrovirals; Antivirals; Immunotherapies; Interferons; Polyethylene glycols; Skin disorder therapies
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata; COVID 2019 infections; Hepatitis B; Hepatitis C
Most Recent Events
- 21 Jun 2022 Cadila Healthcare terminates a phase II clinical trial in COVID-2019 infections in Mexico (Parenteral) due to non availability of eligible patients and slow recruitment(NCT04480138)
- 23 Apr 2021 Launched for COVID-2019 infections in India (SC)
- 23 Apr 2021 Registered for COVID-2019 infections (Restricted Emergency Use Approval in adults) in India (SC)